›› 2001, Vol. 19 ›› Issue (5): 14-307.

• 临床报道 • Previous Articles     Next Articles

A Clinical Trial of Triclabendazole in the Treatment of Human Paragonimiasis skrjabini

HU Peng;LIU Yue han   

  1. Department of Infectious Diseases;The first affiliated hospital;Chongqing University of Medical Sciences;Chongqing 400016
  • Received:1900-01-01 Revised:1900-01-01 Online:2001-10-30 Published:2001-10-30

Abstract:  Objective To observe the therapeutic effect of triclabendazole in patients with paragonimiasis skrjabini. Methods Four patients were treated with triclabendazole at dosage of 10 mg/kg bid for 3 days and were followed up for 6~10 months. The clinical symptoms, chest X ray, hemogram and liver function tests were observed before and after treatment. Results Migratory subcutaneous nodules in three patients all disappeared. Small amount of pleural effusion were absorbed in two patients. Severe headache subsided in a patient with cerebral lesion. MRI showed a bean sized calcified spot in the right frontal region. Chest X ray in 2 patients showed that pulmonary lesions were markedly absorbed and disappeared. There was no adverse effect of the drug.Conclusion Triclabendazole has marked therapeutic effect on paragonimiasis skrjabini. It is safe in administration and well tolerated.

Key words: Paragonimus skrjabini, paragonimiasis, triclabendazole